Last updated: July 30, 2026 · Written and reviewed by the bioaccess® regulatory team
Quick answer
Medical device registration in Latin America requires a local registration holder — called an authorized representative, titular de registro, detentor do registro, or representante legal depending on the country — in every major market except Colombia, where the foreign manufacturer can hold the registration directly through INVIMA with a local legal representative. Typical costs run US$3,000–$8,500 per country for dossier preparation and US$3,800–$8,000 per year for the registration-holder/authorized-representative role, with approvals generally taking about 5–8 months. The single most consequential decision is who holds the registration: the holder controls import continuity, post-market vigilance, distributor leverage, and every future product registration — which makes the authorized-representative structure a market-entry strategy decision, not an administrative one.
Key facts at a glance
- Local holder is the rule; Colombia is the exception. Almost every Latin American regulator issues the registration to a local entity; only Colombia lets the foreign manufacturer hold the Registro Sanitario title directly (with a local representative).
- Two structural questions decide everything: (1) does the country allow only one registration holder per device (single-holder) or several (parallel), and (2) must the registration holder also be the importer of record (fused) or can it authorize a separate importer (decoupled)?
- Cost drivers: dossier prep, the annual authorized-representative fee, government pass-through fees, certified translation, and country-specific prerequisites (e.g., the Dominican Republic’s ONAPI trademark).
- Translation is largely reusable. Most of the region shares Spanish, so a single certified translation set covers all Spanish-speaking markets; only Brazil requires Portuguese.
- Cesión de derechos (transfer of registration rights) exists region-wide, but it only rescues you if your contracts are written for it in advance.
Who can hold a medical device registration in Latin America?
In most of Latin America, regulators do not allow a foreign manufacturer to hold a device registration directly. The registration is issued to a local entity — the authorized representative, titular de registro (Spanish markets), or detentor do registro (Brazil). That local holder becomes the legal face of your device in-country.
Colombia is the structural exception. INVIMA permits the foreign manufacturer to hold the Registro Sanitario title directly, provided it designates a local representante legal. This single difference caps a local partner’s leverage in Colombia and is why many manufacturers anchor their Andean strategy there.
Because the registration is transferable only with the current holder’s cooperation, the choice of holder is a long-term control decision. If a distributor holds it and you later want to switch partners, moving the registration becomes a negotiation — not a formality.
Why the registration holder decision is strategic, not clerical
When a manufacturer places its registration in a partner’s name, five controls transfer with it:
- Regulatory-asset ownership — the registration sits with the partner, affecting future M&A, divestiture, or partner changes.
- Import continuity — the permit holder controls when, how, and in what quantity the device crosses the border.
- Post-market obligations — the holder owns adverse-event reporting, field-safety notices, and recall coordination.
- Distributor leverage — if the holder is also your distributor, they can structurally block you from working with anyone else.
- Future flexibility — line extensions, software companions, and adjacent registrations become tied to the existing dossier and holder.
Which registration-holder architecture should you choose?
| Architecture | How it works | Best fit |
|---|---|---|
| Distributor-as-holder | Your local distributor holds the registration in their own name | Fast and low upfront cost; defensible for an 18–24 month market test, but structurally leveraged against you long-term |
| Independent authorized representative | A neutral specialist holds the registration under a service contract, with no distribution conflict | Preserves distributor flexibility and registration mobility; higher upfront cost, far lower long-term risk |
| Own legal entity | You establish a local subsidiary and register the device directly | Total control; meaningful setup and carrying cost; suited to confirmed revenue at scale |
The right answer is driven by intended market duration, product-roadmap breadth, and revenue concentration — not by whichever option is cheapest in month one.
How much does medical device registration cost in Latin America? (2026 ranges)
Costs vary by country and device risk class. The typical market ranges below reflect 2026 pricing across the region and are useful for budgeting a multi-country program.
| Cost component | Typical 2026 market range | Recurrence |
|---|---|---|
| Dossier preparation & submission (per country, per device) | US$3,000 – $8,500 | One-time |
| Authorized-representative / titular de registro fee | US$3,800 – $8,000 / year | Annual |
| Government / authority pass-through fees | At cost (varies by country) | One-time per submission |
| Certified Spanish translation (full technical set, ~120 pages) | ~US$5,000 – $6,000 (≈$40–$50/page) | One-time, reusable across all Spanish-speaking markets |
| Trademark registration (ONAPI — Dominican Republic only) | US$1,200 – $1,800 per brand/class | One-time |
| Renewal | ~US$1,000 – $1,500 | Recurring (validity is typically 5 years; Colombia ~10) |
| Cesión de derechos legal work (only if transferring an existing registration) | US$1,500 – $4,000 per country | Case-by-case |
Two budgeting rules that save money: translate once and reuse the Spanish set across every Spanish-speaking market, and separate genuinely one-time items (dossier, ONAPI) from recurring items (annual representative fee, renewals) so a multi-country roll-out is modeled correctly.
How long does medical device registration take in Latin America?
Approval timelines typically run about 5–8 months, but they swing with device risk class and the pathway:
- Faster: Mexico’s COFEPRIS equivalence route (recognition of prior FDA, EU, Japan, or Health Canada approval) can compress review dramatically versus the standard path; low-risk classes and notification pathways clear quicker across the region.
- Slower: high-risk classes (e.g., Brazil Class III/IV registro with ANVISA), markets that require in-country testing or certification, and any file that needs a trademark or import-authorization prerequisite resolved first.
Plan the prerequisites early — a missing ONAPI trademark in the Dominican Republic or an unfiled ARCSA import authorization in Ecuador can add months no matter how clean the dossier is.
Country-by-country regulatory summary (2026)
The table below adds the two axes that most guides omit — single-holder vs. parallel registration, and whether the holder must also be the importer of record. These determine both your risk exposure and whether an independent representative can serve you at all.
| Country | Regulator | Who holds the registration | Registration regime | Holder must also be importer? | Notable requirement |
|---|---|---|---|---|---|
| Mexico | COFEPRIS | Local titular del registro | Single-holder | Importer must be license-holding establishment | Equivalence route (FDA/EU/Japan/Canada) can compress review; DIGIPRiS digital platform |
| Brazil | ANVISA | Local detentor do registro (BRH) | Single-holder | Importer must hold ANVISA licensing (AFE) | RDC 751/2022 classification; Portuguese docs; strict technovigilance |
| Colombia | INVIMA | Foreign manufacturer (with local representante legal) | — | Importer must be licensed | The exception to the local-holder rule; ~10-year validity |
| Argentina | ANMAT | Local representante autorizado | Parallel allowed | Yes — fused (holder = importer) | Disposición 2318/2002; 2026 tariff reforms on some devices |
| Chile | ISP | Local entity | Parallel allowed | Decoupled | Only part of the device universe is subject to mandatory registration |
| Peru | DIGEMID | Local droguería | Parallel allowed | Decoupled (importer must be a licensed droguería) | Multiple holders may coexist |
| Ecuador | ARCSA | Local entity | Single-holder | Decoupled — but import authorization must be filed formally through ARCSA (informal letters phased out in 2026) | — |
| Costa Rica | Ministerio de Salud (Regístrelo) | Local holder (CRH) | Single-holder | Decoupled — holder may authorize downstream distributors | — |
| Panama | DNFD / MINSA | Local titular | Single-holder | Yes — fused (single-importer rule) | The titular is the importer of record |
| Uruguay | MSP | Local entity | Parallel (likely) | Yes — fused | — |
| Paraguay | DINAVISA | Local entity | Single-holder | A separate licensed importer can be authorized (importer must be DINAVISA-habilitado) | Confirm holder/importer coupling |
| Guatemala | MSPAS | Local entity | Single-holder | Decoupled — a separate licensed importer is allowed via formal MSPAS/VUPE filing (not a private letter) | — |
| Dominican Republic | DIGEMAPS | Local holder / LAR | Single-holder | Decoupled — via a formal Import Authorization Letter | ONAPI trademark is a prerequisite before the dossier can be filed |
Also local-holder markets: Bolivia, El Salvador, Honduras, Venezuela, and Cuba. Regulatory practice — especially electronic-filing and duplicate-registration rules — can shift; confirm current agency practice before committing a structure.
Official regulator references: INVIMA (Colombia), COFEPRIS (Mexico), ANVISA (Brazil), and ANMAT (Argentina).
One rule that trips up almost every entrant
A private authorization letter does not clear customs. In every country, the entity that physically imports must be a licensed importer that is formally recognized on the registration with the health authority. In markets where the holder must also be the importer (Panama, Argentina, Uruguay), a “registration-only” arrangement with an unrelated logistics company is not viable — the registration and the import license have to sit with the same, or a formally linked, entity.
What is cesión de derechos, and what happens if a distributor won’t transfer?
Cesión de derechos is the legal transfer of registration rights (titularity) from one holder to another. It exists across essentially every Latin American device-registration regime. Whether you actually need it depends on the registration regime:
- Parallel-registration markets (Chile, Peru, Argentina, Uruguay): a cesión is not strictly required. If your current distributor refuses to transfer, you can appoint a new representative, issue a fresh manufacturer authorization, and file a new registration alongside the incumbent’s.
- Single-holder markets (Panama, Ecuador, Dominican Republic, Costa Rica, Guatemala, Paraguay): only one active registration per device exists, so a cesión is the clean path. If the incumbent refuses, a new registration is blocked while theirs stays active — but it is not permanently impossible. Because you are the manufacturer, you control the carta de representación: revoke it, notify the authority, and petition to cancel the incumbent registration (or let it lapse at renewal — they cannot renew without your authorization) while cutting off supply.
The clause that protects you before you ever need it
The reliable way to avoid being held hostage by a distributor in a single-holder market is to write your contracts for it in advance:
- an automatic cesión de derechos (transfer of the registration to you or your nominee) triggered on termination or non-renewal; backed by
- an irrevocable power of attorney letting you sign the transfer or cancellation on the distributor’s behalf.
Together these let you reclaim or cancel a registration without the distributor’s cooperation. Build them into every distributor agreement from day one.
Do you need to translate documentation for every country?
No — and this is where multi-country programs save real money. Most of Latin America shares Spanish, so a single certified Spanish translation set (instructions for use, labeling, technical dossier summary, certificate covers) is reusable across every Spanish-speaking market. Brazil is the exception and requires Portuguese-language documentation. Budget translation as a one-time regional line item, not a per-country charge.
Key takeaways for manufacturers entering Latin America
- Strategic, not clerical. The authorized-representative decision controls imports, post-market vigilance, distributor leverage, and future registrations for the life of the relationship.
- Colombia is the only “hold-it-yourself” market. Everywhere else, plan for a local holder.
- Know your two axes per country — single-holder vs. parallel, and holder-must-import vs. decoupled — before you pick a structure.
- Protect transferability up front with a cesión + irrevocable-POA clause in every distributor contract.
- Translate once, reuse across Spanish markets; budget Portuguese separately for Brazil.
- Resolve prerequisites early — the Dominican Republic’s ONAPI trademark and Ecuador’s formal ARCSA import authorization can gate an otherwise-ready file.
For a country-by-country breakdown of how this maps to a market-entry plan, see the bioaccess® Latin America market-access service.
Frequently asked questions
Who can hold a medical device registration in Latin America?
A local entity — an authorized representative, titular de registro, or detentor do registro — holds the registration in nearly every country. Colombia is the exception: the foreign manufacturer can hold the registration directly through INVIMA with a local legal representative.
Can a foreign manufacturer hold the registration directly anywhere in Latin America?
Yes, in Colombia. INVIMA lets the foreign manufacturer hold the Registro Sanitario title directly, provided it appoints a local representante legal. In the rest of the region the registration is issued to a local holder.
How much does medical device registration cost in Latin America in 2026?
Typical market ranges are US$3,000–$8,500 per country for dossier preparation and US$3,800–$8,000 per year for the registration-holder role, plus government pass-through fees, one-time certified translation (~US$5,000–$6,000 for a reusable Spanish set), and country-specific items such as the Dominican Republic’s ~US$1,200–$1,800 ONAPI trademark.
How long does medical device registration take in Latin America?
Generally about 5–8 months, varying by device risk class and pathway. Mexico’s COFEPRIS equivalence route can be faster; high-risk registrations in Brazil (ANVISA Class III/IV) and files with unresolved prerequisites take longer.
What is a titular de registro / authorized representative?
The local entity that legally holds the device registration in-country and is responsible for import continuity, post-market vigilance, and regulatory correspondence with the health authority.
What is cesión de derechos?
The legal transfer of registration rights (titularity) from one holder to another. It is available region-wide but is only required to change holders in single-holder countries; parallel-registration countries let a new holder file independently.
What if my distributor holds the registration and refuses to transfer it?
In single-holder markets a new registration is blocked while theirs is active, but you retain leverage as the manufacturer: revoke the carta de representación, notify the authority, and cancel or non-renew the incumbent registration. The reliable fix is to include an automatic cesión clause plus an irrevocable power of attorney in the distributor contract from the start.
Which Latin American countries allow parallel registrations?
Chile, Peru, Argentina, and Uruguay generally permit more than one holder to register the same device. Panama, Ecuador, Costa Rica, Guatemala, the Dominican Republic, and Paraguay operate as single-holder systems.
In which countries must the registration holder also be the importer of record?
Panama, Argentina, and Uruguay fuse the two roles — the registration holder must also be the importer. Most other markets allow a decoupled model where the holder authorizes a separate, licensed importer that is formally recognized on the registration.
Do I need to translate my documentation for each country separately?
No. A single certified Spanish translation set is reusable across every Spanish-speaking market. Only Brazil requires Portuguese.
What is the ONAPI trademark requirement in the Dominican Republic?
The Dominican Republic requires a local trademark certificate from ONAPI as a prerequisite before a DIGEMAPS device registration can be filed — a one-time, DR-specific step that does not apply in other countries.
Should my distributor or an independent representative hold my registration?
A distributor-as-holder is fast and cheap but structurally leverages you long-term. An independent authorized representative preserves your ability to change distributors and move the registration, at a higher upfront cost and lower long-term risk. Owning a local entity gives total control at scale.
About bioaccess®
bioaccess® acts as an independent authorized representative / titular de registro across Latin America, holding device registrations on behalf of manufacturers with no distribution conflict — and, where a manufacturer wants a turnkey solution in a market that fuses holder and importer, coordinating a combined registration-holder-plus-importer structure through local affiliates. This preserves your distributor flexibility and keeps your regulatory assets mobile.
Planning a Latin America market-entry? Talk to bioaccess® about your registration strategy →
This guide is general information, not legal or regulatory advice. Regulatory requirements change; confirm current agency practice for your device class and target countries before acting.
Leave a Reply